Emerging Vaccines – Landscape & Forecast – Disease Landscape & Forecast
Vaccination programs have had a revolutionary impact on global public health, not only leading to dramatic reductions in the incidence of infectious diseases but also reducing childhood and adult mortality and improving the quality of life worldwide. Individuals can receive a wide range of vaccinations throughout their life to prevent infections and diseases associated with long-term chronic infections. Although vaccination guidelines may offer strong recommendations for certain vaccines, other vaccines are administered at the discretion of the prescribing physician and the patient. As such, commercial opportunity exists for vaccines that can offer meaningful advantages over current agents. Both the adult and pediatric segments of the vaccines market remain attractive areas for the development of new prophylactic options. This content will include coverage of current and emerging vaccines for key infectious diseases such as HPV, HZ, HBV, meningococcus, pneumococcus, seasonal influenza, RSV, and COVID-19. This content will also assess the impact of the COVID-19 pandemic on the vaccines market.
Questions answered
- What are the sizes of the populations eligible for key vaccination programs in the G7?
- Who are the key decision makers for vaccine purchasing and administration, and how does this group vary by geography?
- What are the key drivers of brand preference in a given vaccine market?
- Which pathogens are associated with the most unmet need in terms of the development of a new or improved vaccine? Which patient pools do experts anticipate will be eligible for these vaccines?
- How will the current vaccines pipeline fulfill areas of unmet need in this market?
- How will key current and emerging vaccines perform commercially?
- How has the COVID-19 pandemic impacted the use of current vaccines?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will feature continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Geographies: United States, EU5, Japan
Primary research: Approximately 16 country-specific interviews with thought-leading infectious disease specialists; supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed events of emerging vaccines by country, segmented by key infectious diseases (HPV, HZ, meningococcus, pneumococcus, seasonal influenza, HBV, RSV, COVID-19).
Forecast: 10-year, annualized, vaccine-level sales and patient share of key vaccines through 2031, segmented by vaccine, geography, and key indications.
Emerging therapies: Registered / preregistered: 5+; Phase III: 12+; Phase II: 20+
Table of contents
- Emerging Vaccines - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Emerging vaccines key findings - December 2022
- Key updates
- Q4 2022
- December 2022
- Q3 2022
- September 2022
- August 2022
- July 2022
- Q2 2022
- June 2022
- May 2022
- April 2022
- Q1 2022
- March 2022
- February 2022
- January 2022
- June 2022
- May 2022
- April 2022
- Q4 2022
- Market outlook
- Key findings
- Market overview
- SWOT analysis
- Market drivers and constraints
- What factors are driving the market for vaccines?
- What factors are constraining the market for vaccines?
- Segment-specific trends
- Major-market sales of vaccines against human papillomavirus, 2021-2031
- Major-market sales of vaccines against herpes zoster, 2021-2031
- Major-market sales of vaccines against meningococcus B, 2021-2031
- Major-market sales of vaccines against meningococcus ACWY, 2021-2031
- Major-market sales of vaccines against pneumococcus, 2021-2031
- Major-market sales of vaccines against seasonal influenza, 2021-2031
- Major-market sales of vaccines against hepatitis B virus, 2021-2031
- COVID-19 vaccines
- Major-market sales of vaccines against COVID-19 virus, 2021-2031
- Respiratory syncytial virus vaccines
- Major-market sales of vaccines against respiratory syncytial virus, 2021-2031
- Key findings
- Forecast
- Market forecast assumptions
- Market forecast dashboard
- Vaccine technologies
- Immunology and vaccine-preventable diseases
- Active immunity
- Classification of vaccines
- Live attenuated vaccines
- Inactivated vaccines
- Polysaccharide vaccines
- Vaccines based on bacterial proteins, polysaccharides, and protein-conjugated polysaccharides
- Recombinant vaccines
- Adjuvants
- Genetic vaccines
- DNA vaccines
- mRNA vaccines
- Immunology and vaccine-preventable diseases
- Epidemiology
- Key findings
- Epidemiology populations
- Definition, methods, and sources used for the population eligible for the RSV vaccine
- Total Population Eligible for the RSV Vaccine: 2021-2031
- Definition, methods, and sources used for the population eligible for the HBV vaccine
- Total population eligible for the hepatitis B vaccine: 2021-2031
- Definition, methods, and sources used for the population eligible for the HPV vaccine
- Total population eligible for the HPV vaccine: 2021-2031
- Definition, methods, and sources used for the population eligible for the shingles vaccine
- Total population eligible for the shingles vaccine: 2021-2031
- Definition, methods, and sources used for the population eligible for the influenza vaccine
- Total population eligible for the influenza vaccine: 2021-2031
- Definition, methods, and sources used for the population eligible for the pneumococcal vaccine
- Total population eligible for the pneumococcal vaccine: 2021-2031
- Definition, methods, and sources used for the population eligible for the meningococcal B vaccine
- Total population eligible for the meningococcal B vaccine: 2021-2031
- Sources used for the population eligible for the meningococcal A, C, W, and Y vaccine
- Total population eligible for the meningococcal A, C, W, and Y vaccine: 2021-2031
- Definition, methods, and sources used for the population eligible for the COVID-19 vaccine
- Total population eligible for the COVID-19 vaccine: 2021-2031 (thousands)
- Sources used for vaccination rates
- Number of vaccinated patients: 2021-2031 (thousands)
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials of vaccines
- Key current therapies
- Overview
- Mechanism of action of key current vaccines
- Current vaccines
- Advantages and disadvantages of Gardasil 9
- Advantages and disadvantages of Gardasil
- Advantages and disadvantages of Cervarix
- Expert insight: HPV vaccines
- Vaccination guidelines
- Country-specific HPV vaccination guidelines
- Factors influencing vaccine selection in HPV
- Advantages and disadvantages of Prevnar 13
- Advantages and disadvantages of Pneumovax 23
- Prevnar 20
- Advantages and disadvantages of Prevnar 20
- Vaxneuvance
- Advantages and disadvantages of Vaxneuvance
- Expert insight: Pneumococcal vaccines
- Vaccination guidelines
- Country-specific pneumococcal vaccination guidelines
- Factors influencing vaccine selection for pneumococcus
- Meningococcal vaccines
- Advantages and disadvantages of Menveo
- Advantages and disadvantages of Menactra
- Advantages and disadvantages of Nimenrix
- MenQuadfi
- Advantages and disadvantages of MenQuadfi
- Advantages and disadvantages of Bexsero
- Advantages and disadvantages of Trumenba
- Expert insight: Meningococcal vaccines
- Vaccination guidelines
- Country-specific meningococcal vaccination guidelines
- Factors influencing vaccine selection for meningococcus
- Advantages and disadvantages of Fluzone
- Advantages and disadvantages of Flulaval
- Advantages and disadvantages of Fluarix
- Current minor vaccines used for seasonal influenza
- Expert insight: Seasonal influenza vaccines
- Vaccination guidelines
- Country-specific seasonal influenza vaccination guidelines
- Factors influencing vaccine selection for seasonal influenza
- Advantages and disadvantages of Engerix-B
- Advantages and Disadvantages of Recombivax HB / HBVaxPRO
- Advantages and disadvantages of Heplisav-B
- Sci-B-Vac (PreHevbrio)
- Advantages and disadvantages of Sci-B-Vac
- Expert insight: hepatitis B virus vaccines
- Vaccination guidelines
- Factors influencing vaccine selection for hepatitis B virus
- Country-specific hepatitis B virus vaccination guidelines
- Advantages and disadvantages of Comirnaty
- Advantages and disadvantages of Spikevax
- Advantages and disadvantages of Vaxzevria / AZD1222
- Advantages and disadvantages of Johnson & Johnson COVID-19 vaccine
- Advantages and disadvantages of Nuvaxovid / NVX-CoV2373
- Advantages and disadvantages of VLA-2001
- Expert insight: COVID-19 vaccines
- Vaccination guidelines
- Factors influencing vaccine selection for COVID-19
- Advantages and disadvantages of Shingrix
- Advantages and disadvantages of Zostavax
- Vaccination guidelines
- Country-specific HZ vaccination guidelines
- Factors influencing vaccine selection for herpes zoster
- Expert insight: herpes zoster vaccines
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs for vaccines
- Top unmet needs for vaccines: current and future attainment
- Expert insight: unmet need for vaccines
- Current and future attainment of unmet needs for vaccines
- Emerging therapies
- Key findings
- Key emerging therapies
- Key vaccines in development
- Estimated launch dates of key emerging vaccines
- Oral flu vaccine profile
- Analysis of the clinical development program for oral flu vaccine
- Expectations for launch and sales opportunity of oral flu vaccine for seasonal influenza
- M-001 profile
- M-001 clinical development
- Expectations for launch and sales opportunity of M-001 for seasonal influenza
- NasoVAX profile
- Analysis of the clinical development program for NasoVAX
- Expectations for launch and sales opportunity of NasoVAX for seasonal influenza
- NanoFlu profile
- Analysis of the clinical development program for NanoFlu
- Expectations for launch and sales opportunity of NanoFlu for seasonal influenza
- mRNA-1010 profile
- Analysis of the clinical development program for mRNA-1010
- Expectations for launch and sales opportunity of mRNA-1010
- PF-07252220 profile
- Analysis of the clinical development program for PF-07252220
- Expectations for launch and sales opportunity of PF-07252220
- ResVax profile
- Analysis of the clinical development for ResVax
- Expectations for launch and sales opportunity of ResVax for RSV
- MVA-BN RSV profile
- Analysis of the clinical development program for MVA-BN RSV
- Expectations for Launch and Sales Opportunity of MVA-BN-RSV for RSV
- JNJ-64400141 profile
- Analysis of the clinical development program for JNJ-64400141
- Expectations for Launch and Sales Opportunity of JNJ-64400141
- PF-06928316 profile
- Analysis of the clinical development program for PF-06928316
- Expectations for launch and sales opportunity of PF-06928316
- GSK-3888550A profile
- Analysis of the clinical development program for GSK-3888550A
- Expectations for Launch and Sales Opportunity of GSK-3888550A
- GSK-3844766A profile
- Analysis of the clinical development program for GSK-3844766A
- Expectations for launch and sales opportunity of GSK-3844766A
- mRNA-1345 profile
- Analysis of the clinical development program for mRNA-1345
- Expectations for launch and sales opportunity of mRNA-1345
- Expert insight: respiratory syncytial virus vaccines
- Meningococcal vaccines
- GSK-3536819A
- GSK-3536819A profile
- Analysis of the clinical development program for GSK-3536819A
- Expectations for launch and sales opportunity of GSK-3536819A
- PF-06886992
- Analysis of the clinical development program for PF-06886992
- Expectations for launch and sales opportunity of PF-06886992
- Expert insight: Meningococcal vaccines
- COVID-19 vaccines
- CoronaVac
- Analysis of the clinical development program for CoronaVac
- Expectations for launch and sales opportunity of CoronaVac for COVID-19
- SP-0253
- SP-0253 profile
- Analysis of the clinical development program for SP-0253
- Expectations for launch and sales opportunity of SP-0253 for COVID-19
- UB-612
- UB-612 profile
- Analysis of the clinical development program for UB-612
- Expectations for launch and sales opportunity of UB-612 for COVID-19
- KD-414
- Analysis of the clinical development program for KD-414
- Expectations for launch and sales opportunity of KD-414 for COVID-19
- PHH-1V
- PHH-1V profile
- Analysis of the clinical development program for PHH-1V
- Expectations for launch and sales opportunity of PHH-1V for COVID-19
- DS-5670
- DS-5670 profile
- Analysis of the clinical development program for DS-5670
- Expectations for launch and sales opportunity of DS-5670 for COVID-19
- SKYCovione (GBP-510)
- SKYCovione (GBP-510) profile
- Analysis of the clinical development program for SKYCovione (GBP-510)
- Expectations for launch and sales opportunity of SKYCovione (GBP-510) for COVID-19
- S-268019
- Analysis of the clinical development program for S-268019
- Expectations for launch and sales opportunity of S-268019 for COVID-19
- Pneumococcal vaccines
- V-116
- V-116 profile
- Analysis of the clinical development program for V-116
- Expectations for launch and sales opportunity of V-116
- Expert insight: pneumococcal vaccines
- Additional mid- to late-phase emerging vaccines of note
- Early-phase pipeline analysis
- Select vaccines in early-phase development
- Key findings
- Access & reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations for vaccines: United States
- General reimbursement environment: United States
- Key market access considerations for vaccines: EU5
- General reimbursement environment: EU5
- Key market access considerations for vaccines: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Vaccines bibliography
- Key findings
Sukhvinder Singh, M.Tech., is a senior analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. He has several years of experience providing research and analytics support in the pharmaceutical domain. He has worked in numerous therapy areas, including ophthalmology, dermatology, neurology, and rare diseases. Prior to joining Clarivate, Mr. Singh was an assistant project manager on the forecasting and analytics team at DelveInsight Business Research. He was responsible for preparing epidemiology and market research reports, which included pipeline assessments, sales forecasting, and commercial opportunity assessments. He earned his master’s degree in technology and biotechnology at Amity University in Noida, India.
Jagriti Prasad, M.P.H., is an associate epidemiologist at Clarivate. Prior to joining the company, she worked on a research project exploring trends in a rare cancer and its subtype using data spanning 44 years in the largest cancer registry of northern England (NRYPMDR). She obtained her M.P.H. from Newcastle University in the United Kingdom and her B.D.S. from Manipal University in India.